Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

First quarter total revenue of $139 million, Crysvita® revenue of$103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total revenue between$640 million to $670 million, Crysvita revenue of$460 million to $480 million, and Dojolvi revenue of$90 million to $100 million UX111, an investigational treatment for Sanfilippo syndrome, biologics license application (BLA) on track for PDUFA action date of August 18, 2025 NOVATO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pha ...